Kairos Pharma Ltd (KAPA) Stock Price, Quote & News

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 948 2356

Website: kairospharma.com

Address:

2355 Westwood Boulevard, Suite 139, Los Angeles, United States

Xtracked Mar. 21 at 4:29 PM

$KAPA "AACR" ... Big difference.

1 · Reply

Xtracked Mar. 20 at 2:58 PM

$KAPA Here's ur hopium fix... AARC is 4/17. Abstracts will be announced by 4/3. A must IMHO. 4/21 ...ASCO presentations announced. Is it time?? Are they ready w something good??

0 · Reply

TraderBuckNKY Mar. 20 at 2:21 PM

$KAPA ...what a shame...so, so mis-managed, OR worse . . .

0 · Reply

joaneegell Mar. 19 at 5:45 PM

$KAPA just when I thought it couldn't get any better

0 · Reply

newyork1979 Mar. 18 at 7:50 PM

TAOP could easily 3X from here - 900k FLoat with no dilution - Robotics / AI merger coming with a company that has HUGE customers like mcdonalds/KFC/Starbucks - TAOP is only valued around $12M , very undervalued. - Shorts are trapped and will be forced to buyback all their shares which will cause a Mother of all short squeezes. $SYRA $KAPA $F $NOK $IUB watching

0 · Reply

Xtracked Mar. 18 at 6:31 PM

$KAPA John Yu are letting everybody suffer...why? SP has tanked and Yu did nothing...

1 · Reply

Oldshoe Mar. 17 at 8:28 PM

$KAPA Yes, would like to see that too. Someone please share a link if you have it. Thanks.

2 · Reply

TraderBuckNKY Mar. 17 at 7:29 PM

$KAPA ...been trying to find an audio/video recording of Neil's presentation today....to no avail...,anybody know/find anything...?

0 · Reply

Xtracked Mar. 17 at 12:32 PM

$KAPA Is speaking first @ 11:00. Looks to be a nothing burger as always. Low expectations... again

2 · Reply

Xtracked Mar. 16 at 1:55 PM

$KAPA Is running out of $. One would assume that Neil will give updates on 105 and closing of acquisition w timelines/ forecast

1 · Reply

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics

Feb 26, 2026, 7:00 AM EST - 23 days ago

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics

Jan 20, 2026, 8:00 AM EST - 2 months ago

Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

Dec 17, 2025, 8:15 AM EST - 3 months ago

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Nov 4, 2025, 8:00 AM EST - 4 months ago

Kairos Pharma Provides Shareholder Update

Oct 20, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Oct 7, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Sep 18, 2025, 8:00 AM EDT - 6 months ago

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Sep 11, 2025, 8:00 AM EDT - 6 months ago

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Sep 3, 2025, 8:15 AM EDT - 7 months ago

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Sep 2, 2025, 4:05 PM EDT - 7 months ago

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Jul 28, 2025, 12:28 PM EDT - 8 months ago

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Jul 16, 2025, 8:30 AM EDT - 8 months ago

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 15, 2025, 2:08 PM EDT - 8 months ago

Why Is Kairos Pharma Stock Surging On Tuesday?

Jul 15, 2025, 8:00 AM EDT - 8 months ago

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jun 3, 2025, 8:15 AM EDT - 10 months ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 6, 2025, 8:00 AM EDT - 11 months ago

Kairos Pharma, Ltd. Announces Participation in the D.

Apr 28, 2025, 8:00 AM EDT - 11 months ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 11 months ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Mar 20, 2025, 7:30 AM EDT - 1 year ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Feb 26, 2025, 7:00 AM EST - 1 year ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Feb 18, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Feb 11, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 6, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Jan 28, 2025, 8:15 AM EST - 1 year ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 21, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Provides Business Update and Outlook into 2025

Jan 7, 2025, 8:15 AM EST - 1 year ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Dec 16, 2024, 12:15 PM EST - 1 year ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 3, 2024, 8:30 AM EST - 1 year ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Nov 26, 2024, 8:30 AM EST - 1 year ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 9, 2024, 4:30 PM EDT - 1 year ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 24, 2024, 4:20 PM EDT - 1 year ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Feb 14, 2024, 6:16 PM EST - 2 years ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Xtracked Mar. 21 at 4:29 PM

$KAPA "AACR" ... Big difference.

1 · Reply

Xtracked Mar. 20 at 2:58 PM

$KAPA Here's ur hopium fix... AARC is 4/17. Abstracts will be announced by 4/3. A must IMHO. 4/21 ...ASCO presentations announced. Is it time?? Are they ready w something good??

0 · Reply

TraderBuckNKY Mar. 20 at 2:21 PM

$KAPA ...what a shame...so, so mis-managed, OR worse . . .

0 · Reply

joaneegell Mar. 19 at 5:45 PM

$KAPA just when I thought it couldn't get any better

0 · Reply

newyork1979 Mar. 18 at 7:50 PM

0 · Reply

Xtracked Mar. 18 at 6:31 PM

$KAPA John Yu are letting everybody suffer...why? SP has tanked and Yu did nothing...

1 · Reply

Oldshoe Mar. 17 at 8:28 PM

$KAPA Yes, would like to see that too. Someone please share a link if you have it. Thanks.

2 · Reply

TraderBuckNKY Mar. 17 at 7:29 PM

$KAPA ...been trying to find an audio/video recording of Neil's presentation today....to no avail...,anybody know/find anything...?

0 · Reply

Xtracked Mar. 17 at 12:32 PM

$KAPA Is speaking first @ 11:00. Looks to be a nothing burger as always. Low expectations... again

2 · Reply

Xtracked Mar. 16 at 1:55 PM

$KAPA Is running out of $. One would assume that Neil will give updates on 105 and closing of acquisition w timelines/ forecast

1 · Reply

GIPARK Mar. 16 at 1:26 PM

$KAPA

0 · Reply

Xtracked Mar. 11 at 1:55 PM

$KAPA Is horrible at promoting. Nobody will know that Neil is speaking next week. I do not expect anything from this as they are keeping info from investors

0 · Reply

GIPARK Mar. 11 at 1:33 PM

$KAPA

0 · Reply

ezcheezie Mar. 10 at 1:20 PM

$KAPA

2 · Reply

Xtracked Mar. 9 at 6:53 PM

$KAPA Someone poke it with a stick

0 · Reply

Xtracked Mar. 9 at 12:02 AM

$KAPA

0 · Reply

GIPARK Mar. 8 at 11:35 AM

$KAPA wake up

0 · Reply

GIPARK Mar. 6 at 8:29 AM

$KAPA

0 · Reply

Richricx Mar. 5 at 10:11 PM

$KAPA Two Green Hammer Candle MACD still turned upward I’ll take that any day, ESPECIALLY today

0 · Reply

RLS71 Mar. 5 at 9:05 PM

$KAPA Schwab has $.656 close... not bad on a very ruff day.

1 · Reply

Xtracked Mar. 5 at 3:11 PM

$KAPA Don't hold ur breath...lots of fkery going on. Maybe shorts expected drop after acquisition. Large overnight purchases on same night as last weeks overnight purchases...covering? IDK

0 · Reply

Richricx Mar. 5 at 1:31 PM

$KAPA Retail will be buying this at $2+

1 · Reply

Market Cap	12.48M
Revenue (ttm)	0.00
Net Income (ttm)	-2.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	216,400
Avg Vol	626,384
Day's Range	N/A - N/A
Shares Out	20.82M
Stochastic %K	53%
Beta	2.28
Analysts	Strong Sell
Price Target	$8.33